<DOC>
	<DOCNO>NCT01187836</DOCNO>
	<brief_summary>In study , TRV120027 ( placebo ) intravenous infusion give people heart failure learn effect TRV120027 . The result study help choose proper range TRV120027 dose use future research study involve patient acute decompensated heart failure .</brief_summary>
	<brief_title>Study Evaluate Effects TRV120027 Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Diagnosis congestive heart failure make least 3 month prior screen NYHA Class III IV heart failure , ejection fraction &lt; /= 35 % , opinion investigator , rightheart catheterization clinically indicate . Baseline mean PCWP &gt; /= 20 mmHg Systolic blood pressure screen must &gt; /= 100 mmHg . Heart rate screening must &lt; /= 90 bpm . Any significant disease condition would interfere interpretation safety efficacy study determine Investigator base medical history , physical examination laboratory test . Significant valve disease Current sign symptom acute myocardial ischemia acute coronary syndrome ( ACS ) coronary revascularization past 3 month . Sustained uncontrolled ventricular arrhythmia . Inclusion patient atrial fibrillation heart rate â‰¤ 90 bpm permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>